[ Cancer Care Delivery Research ]
Cancer Care Delivery Research (CCDR) encompasses a multidisciplinary field of scientific investigation. It examines how social factors, financing systems, organizational structures and processes, health technologies, healthcare provider and individual behaviors affect cancer outcomes, access to and quality of care, cancer care costs, and the health and well-being of cancer patients and survivors.
Lili Wang, MD
Section Chair, Oncology/Hematology Program
Contra Costa Regional Medical Center
BATI-NCORP Cancer Care Delivery Research
NCORP is designing trials to improve cancer prevention, cancer control, screening, and post-treatment management. The new program will have an expanded portfolio of clinical trials and other studies, including an emphasis on cancer care delivery research. Cancer care delivery research within NCORP focuses on diverse and multi-level factors (e.g. social, financing systems, process, technology, and others) that affect access to and quality of care in the community. The BATI-NCORP will bring this new knowledge into clinical trials conducted in the community, where most patients receive their care. The NCORP network will identify and evaluate the critically needed interventions that reduce cancer risk and incidence, enhance cancer patients’ quality of life, and increase access to clinical trials and cancer care delivery research for minority, rural, and other underserved patient populations.
An early example of Cancer Care Delivery Research in which the BATI-NCORP was the second leading participant in a nation-wide pilot study follows:
SWOG S1204: This study seeks to discover how common human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) infections are among new cancer patients.
Screening newly diagnosed cancer patients for HIV, HBV and/or HCV infections is very important. If a doctor treats a cancer patient without knowing that the patient has one of these viruses, it could cause severe problems or even death. The Center for Disease Control recommends Hepatitis B screening for all patients undergoing treatment with certain types of drugs that can affect the immune system (like some of the drugs used to treat cancer). Despite these recommendations, cancer patients are not always routinely screened for these viruses. The BATI-NCORP is seeking to find cost-effective ways for cancer treatment centers to test patients for HIV, HBV, and HCV. The ultimate goal is to learn the best way to find and treat cancer patients who have these viruses.
Cancer Disparities Research and Minority Populations
Cancer Disparities Research focuses on inconsistencies in clinical trial outcomes and cancer care delivery related to the most serious, prevalent cancers and cancer-related problems which disproportionately affect racial/ethnic minorities and underserved populations. It includes studies to: enhance participation of racial/ethnic minorities and the underserved in clinical trials; address determinants of disparities (for example, social and health care system factors, co-morbidities, and genomics); and evaluate differential outcomes in minority/underserved populations.